Carter's Reports Over 50% Profit Decline, Cuts Dividend by 69%, and Adopts Poison Pill Amid Restructuring

summarizeSummary

Carter's reported a steep decline in fiscal 2025 net income and EPS, leading to a significant 69% cut in its quarterly dividend. The company is implementing a major restructuring plan, including store closures and workforce reductions, and adopted a poison pill in response to shareholder activity.

check_boxKey Events

• Significant Profit Decline

  Consolidated net income decreased by 50.5% to $91.8 million, and diluted EPS fell by 50.6% to $2.53 for fiscal year 2025, despite a 1.9% increase in net sales.

• 69% Quarterly Dividend Cut

  The Board declared a quarterly cash dividend of $0.25 per common share, representing a 69% reduction from the $0.80 per share paid in the first quarter of fiscal 2025. Total dividends paid for FY2025 were $1.55 per share, down from $3.20 in FY2024.

• Organizational Restructuring and Store Closures

  Initiated an organizational restructuring in Q3 2025, reducing office-based roles by approximately 15% for an expected $35 million in annual savings starting FY2026. Plans to close approximately 150 lower-margin stores (representing $110 million in FY2025 net sales) through fiscal 2028, with 35 closed in FY2025 and 60 expected in FY2026.

• Adoption of Stockholder Rights Agreement (Poison Pill)

  The Board authorized a limited-duration stockholder rights agreement on September 22, 2025 (previously disclosed in an 8-K on September 24, 2025), in response to a rapid accumulation of shares by a third party. The agreement expires September 21, 2026, and triggers at 15% beneficial ownership (20% for 13G filers).

auto_awesomeAnalysis

Carter's annual report for fiscal year 2025 reveals a challenging financial performance, with net income and diluted EPS both declining by over 50% compared to the prior year. This significant drop in profitability led to a substantial 69% reduction in the quarterly cash dividend, a clear negative signal to investors. The company is undertaking a major organizational restructuring, including a 15% reduction in office-based workforce and plans to close approximately 150 lower-margin stores through fiscal 2028, aiming for $35 million in annual savings. These actions, while intended to improve future profitability, highlight current operational challenges. Furthermore, the adoption of a limited-duration stockholder rights agreement (poison pill) in September 2025, previously disclosed in an 8-K, indicates a defensive posture against potential unsolicited takeover attempts, suggesting vulnerability. The company also refinanced its debt, issuing new senior notes with a higher interest rate, and anticipates a material impact from new tariffs in fiscal 2026, adding to future uncertainty. Investors should monitor the effectiveness of the restructuring efforts and the impact of tariffs on future financial performance.